Contributing factors of temozolomide resistance in MCF-7 tumor xenograft models

Cancer Biology and Therapy

Volumn 6, Issue 6, 2007, Pages 891-897

  Kato, Yoshinori ^a   Okollie, Baasil ^a   Raman, Venu ^a   Vesuna, Farhad ^a   Zhao, Ming ^a   Baker, Sharyn D ^a   Bhujwalla, Zaver M ^a   Artemov, Dmitri ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Chemotherapy; Drug resistance; MCF 7; MCF 7 ADR; Temozolomide; Tumor vascular function

Indexed keywords

DOXORUBICIN; MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; P21 ACTIVATED KINASE; PROTEIN P53; TEMOZOLOMIDE; VASCULOTROPIN; DACARBAZINE; DRUG DERIVATIVE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRAIN MCF 7; DRUG EXPOSURE; DRUG RESISTANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; TUMOR XENOGRAFT; VASCULAR TUMOR; ANIMAL; BIOLOGICAL MODEL; CANCER TRANSPLANTATION; DRUG DELIVERY SYSTEM; METABOLISM; MOUSE MUTANT; TIME; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DACARBAZINE; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MICE; MICE, SCID; MODELS, BIOLOGICAL; NEOPLASM TRANSPLANTATION; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 42449156775     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.6.6.4096     Document Type: Article

References (37)

1. Teicher BA, Herman TS, Holden SA, Wang YY, Pfeffer MR, Crawford JW, Frei IIIrd E. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 1990; 247:1457-61.
2. Primeau AJ, Rendon A, Hedley D, Lilge L, Tannock IF. The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res 2005; 11:8782-8.
3. Minko T, Kopecková P, Pozharov V, Jensen KD, Kopecek J. The influence of cytotoxicity of macromolecules and of VEGF gene modulated vascular permeability on the enhanced permeability and retention effect in resistant solid tumors. Pharm Res 2000; 17:505-14.
4. Artemov D, Solaiyappan M, Bhujwalla ZM. Magnetic resonance pharmacoangiography to detect and predict chemotherapy delivery to solid tumors. Cancer Res 2001; 61:3039-44.
5. Kato Y, Okollie B, Artemov D. Non-invasive 1H/13C magnetic resonance spectroscopic imaging of the intratumoral distribution of temozolomide. Magn Reson Med 2006; 55:755-61.
6. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23:1011-27.
7. Sezaki H, Hashida M. Macromolecule-drug conjugates in targeted cancer chemotherapy. Crit Rev Ther Drug Carrier Syst 1984; 1:1-38.
8. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46:6387-92.
9. Bhujwalla ZM, Artemov D, Natarajan K, Ackerstaff E, Solaiyappan M. Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts. Neoplasia 2001; 3:143-53.
10. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res 2000; 6:2585-97.
11. 6-benzylguanine plus chloroethylnitrosoureas in human breast cancer. Cancer Chemother Pharmacol 1999; 44:319-26.
12. Ma J, Murphy M, O'Dwyer PJ, Berman E, Reed K, Gallo JM. Biochemical changes associated with a multidrug-resisant phenotype of a human glioma cell line with temozolomide-acquired resisance. Biochem Pharmacol 2002; 63:1219-28.
13. 99mTc-sestamibi and doxorubicin to monitor inhibition of P-glycoprotein function. Br J Cancer 2001; 84:367-73.
14. Ogretmen B, Safa AR. Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells. Oncogene 1997; 14:499-506.
15. 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 1999; 5:309-17.
16. Kim HK, Lin CC, Parker D, Veals J, Lim J, Likhari P, Statkevich P, Marco A, Nomeir AA. High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl) -imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma. J Chromatogr B Biomed Sci Appl 1997; 703:225-33.
17. Kim H, Likhari P, Parker D, Statkevich P, Marco A, Lin CC, Nomeir AA. High-performance liquid chromatographic analysis and stability of anti-tumor agent temozolomide in human plasma. J Pharm Biomed Anal 2001; 24:461-8.
18. Chowdhury SK, Laudicina D, Blumenkrantz N, Wirth M, Alton KB. An LC/MS/MS method for the quantitation of MTIC (5-(3-N-methyltriazen-1-yl)- imidazole-4-carboxami de), a bioconversion product of temozolomide, in rat and dog plasma. J Pharm Biomed Anal 1999; 19:659-68.
19. Hammond LA, Eckardt JR, Baker SD, Eckhardt SG, Dugan M, Forral K, Reidenberg P, Statkevich P, Weiss GR, Rinaldi DA, Von Hoff DD, Rowinsky EK. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol 1999; 17:2604-13.
20. Denny BJ, Wheelhouse RT, Stevens MF, Tsang LL, Slack JA. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 1994; 33:9045-51.
21. 6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model. Int J Cancer 2002; 100:615-7.
22. Brock CS, Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I, Roddie M, Glaser M, Brampton MH, Rustin GJ. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 1998; 58:4363-7.
23. Middleton MR, Kelly J, Goodger S, Thatcher N, Margison GP. Four-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenografts. Cancer Chemother Pharmacol 2000; 45:15-20.
24. Brada M, Judson I, Beale P, Moore S, Reidenberg P, Statkevich P, Dugan M, Batra V, Cutler D. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 1999; 81:1022-30.
25. Schering corporation. Product informaion: TEMODAR® (temozolomide) CAPSULES. United States, NJ: Kenilworth, 2003.
26. Morrison PR, Sendroy Jr J. Surface area relationships: Mammals. In: Spector WS, ed. Handbook of biological data III Development and morphology. Philadelphia: W. B. Saunders, 1956:175.
27. Davidson IW, Parker JC, Beliles RP. Biological basis for extrapolation across mammalian species. Regul Toxicol Pharmacol 1986; 6:211-37.
28. Kato Y, Onishi H, Machida Y. N-Succinyl-chitosan as a drug carrier: Water-insoluble and water-soluble conjugates. Biomaterials 2004; 25:907-15.
29. Pathak AP, Artemov D, Ward BD, Jackson DG, Neeman M, Bhujwalla ZM. Characterizing extravascular fluid transport of macromolecules in the tumor interstitium by magnetic resonance imaging. Cancer Res 2005; 65:1425-32.
30. Pathak AP, Artemov D, Neeman M, Bhujwalla ZM. Lymph node metastasis in breast cancer xenografts is associated with increased regions of extravascular drain, lymphatic vessel area, and invasive phenotype. Cancer Res 2006; 66:5151-8.
31. Jain RK. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev 1990; 9:253-66.
32. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005; 307:58-62.
33. Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994; 271:58-65.
34. Machein MR, Kullmer J, Fiebich BL, Plate KH, Warnke PC. Vascular endothelial growth factor expression, vascular volume, and, capillary permeability in human brain tumors. Neurosurgery 1999; 44:732-40, (discussion 40-41).
35. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004; 64:3731-6.
36. Chadderton A, Villeneuve DJ, Gluck S, Kirwan-Rhude AF, Gannon BR, Blais DE, Parissenti AM. Role of specific apoptotic pathways in the restoration of paclitaxel-induced apoptosis by valspodar in doxorubicin-resistant MCF-7 breast cancer cells. Breast Cancer Res Treat 2000; 59:231-44.
37. Auger N, Thillet J, Wanherdrick K, Idbaih A, Legrier ME, Dutrillaux B, Sanson M, Poupon MF. Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line. Mol Cancer Ther 2006; 5:2182-92.